Mansour, John C.
https://orcid.org/0000-0001-6346-9429
Mayo Clinic
The University of Texas Southwestern Medical Center
Citations 1
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024
Churpek, Jane , Kohlmann, Wendy , Al‐Hilli, Zahraa , Friedman, Susan , Hagemann, Andrea R. , Hendrix, Ashley, Hutton, Mollie L., Kassem, Nawal , Khan, Seema, Khoury, Katia , Kurian, Allison W. , Laronga, Christine , Mak, Julie , Mansour, John C. , McDonnell, Kevin , Menendez, Carolyn S. , Merajver, Sofía D. , Norquist, Barbara S., Offit, Kenneth , Rash, Dominique , Reiser, Gwen , Senter-Jamieson, Leigha, Shannon, Kristen M. , Visvanathan, Kala , Welborn, Jeanna, Wick, Myra , Wood, Marie , Yurgelun, Matthew B. , Dwyer, Mary A., Darlow, Susan, Norquist, Barbara M. , Churpek, Jane E. , Visvanathan, Kala , Kurian, Allison W , Norquist, Barbara , Churpek, Jane E , Daly, Mary Beryl , Pal, Tuya , Maxwell, Kara N. , Arun, Banu , Buys, Saundra S. , Cheng, Heather H. , Domchek, Susan M. , Giri, Veda N. , Goggins, Michael , Karlan, Beth Y.
Journal of the National Comprehensive Cancer Network | October 12, 2023 | Volume: 21 | Issue: 10 | Pages: 1000-1010
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1 , BRCA2 , CDH1 , PALB2 , PTEN , and TP53 , and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.